The Japanese group Fujifilm make a series of clinical trials to test the effectiveness of your influenza medicine Avigan (favipiravir) to treat patients affected by COVID-19, after obtaining positive results from other studies conducted in China with this product.
If the efficacy of the antiviral favipiravir for the treatment of COVID-19 is verified in clinical trials, the drug could be produced at low cost in Mexico, it is already generic and any country could manufacture it.
In accordance with Millennium, the Coordination of National Institutes of Health presented to the Federal Commission for Protection against Health Risks (Coffepris) a protocol for conducting a clinical trial with the Japanese antiviral favipiravir, whose first studies in that country, China and Russia have yielded encouraging results.
Favipiravir prevents the coronavirus from reproducing and is very effective at an early stage of the disease.
Enrique Giraud de Haro, General Director of Fujifilm de México he said in an interview for Millennium that, until now, the company has not received any type of profit for the controlled use of the antiviral, it would be until the governments authorize its use for the treatment against the virus. Its sale could be opened to the public to be able to market it, but he stressed that It is already a generic, so its manufacture would not be exclusive to Fujifilm.
For his part, Russia It announced on May 13 that it obtained good results with the use of that drug, while in March, China concluded a clinical investigation that demonstrated the efficacy of favipiravir without observing adverse reactions.
So far, 15 clinical trials: Italy, Iran, the United States, Egypt, Thailand, China, the United Kingdom, France, Brazil and Saudi Arabia, according to the ClinicalTrival.gob platform.
On the other hand, media reports indicate that it is also studied in Spain, Turkey, Ukraine, the Czech Republic, Hungary and Indonesia.
In the interview, Giraud de Haro stressed that Fujifilm normally relates to the manufacture of film and photographic equipment, but since its founding it has been involved in graphic arts and radiography equipment. In addition, the company has long acquired some drug companies, which is why they created Avigan.
In this sense, the company has also collaborated with others teams doctors in Mexico, such as the distribution of 40 mobile X-ray equipment for the diagnosis of pneumonia, as well as endoscopy and ultrasound equipment, and molecular readers of the coronavirus tests used to diagnose COVID-19.
It should be noted that the Avigan obtained in 2014 the Japanese government approval for production and sold as an influenza medicine, but has never been distributed on the market.
UNAM develops laboratory to create vaccine
In the rush to get a cure for coronavirus, lThe maximum house of studies is already working on the development of a laboratory level 3 that will be used to create a vaccine against COVID-19.
The above, with support from the Mexico City government and the Secretary of Education, Science, Technology and Innovation of Mexico City (SECTeI).
The level 3 biosafety laboratory must provide substantial security measures, since the coronavirus, which is a highly contagious pathogen, therefore, UNAM could place this space in the Faculty of Veterinary Medicine and Animal Husbandry.
"To make vaccines of a virus as special and risky as SARS-Cov-2, which produces the disease COVID-19, requires a specialized laboratory where there is not the slightest possibility that it could come out or there could be any contagion”, Explained in a virtual press conference the SECTeI secretary, Rosaura Ruiz Gutiérrez.
Even if The amount of investment in this laboratory was not specified nor the date when it would be ready, the SECTeI secretary said that there would be relevant support from the government of the Mexican capital..
MORE ABOUT THESE THEMES
Clinical Trials of Favipiravir Flu Against Coronavirus Started in Japan
UNAM develops laboratory to create vaccine against COVID-19